Damora Therapeutics (DMRA) EBITDA (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of EBITDA data on file, last reported at -$27.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 1094.46% year-over-year to -$27.8 million; the trailing twelve-month figure through Mar 2026 stood at -$234.6 million (down 1166.86% YoY), and the FY2025 full-year result was -$209.1 million, down 862.78% from the prior year.
• EBITDA for Q1 2026 stood at -$27.8 million, up from -$200.8 million in the prior quarter.
• Across five years, EBITDA topped out at -$2.3 million in Q1 2025 and bottomed at -$200.8 million in Q4 2025.
• The 5-year median for EBITDA is -$8.0 million (2023), against an average of -$21.1 million.
• Peak annual rise in EBITDA reached 57.87% in 2025, while the deepest fall reached 2646.71% in 2025.
• A 5-year view of EBITDA shows it stood at -$12.4 million in 2022, then jumped by 50.43% to -$6.1 million in 2023, then declined by 19.02% to -$7.3 million in 2024, then slumped by 2646.71% to -$200.8 million in 2025, then soared by 86.14% to -$27.8 million in 2026.
• The last three EBITDA figures came in at -$27.8 million (Q1 2026), -$200.8 million (Q4 2025), and -$3.1 million (Q3 2025), per Business Quant data.

Peer Comparison